Cost-effectiveness of pharmacological therapies for people with Alzheimer’s disease and other dementias: a systematic review and meta-analysis

[1] Wimo A(2017)The worldwide costs of dementia 2015 and comparisons with 2010 Alzheimers Dement 13 1-7

[2] Guerchet M(2018)Dementia: assessment, management and support: summary of updated NICE guidance BMJ 361 k2438-90

[3] Ali G-C(2007)Cost–effectiveness of treatments for Alzheimer’s dementia Expert Rev Pharmacoecon Outcomes Res 7 83-612

[4] Wu Y-T(2013)Screening for cognitive impairment in older adults: a systematic review for the US Preventive Services Task Force Ann Intern Med 159 601-2734

[5] Prina AM(2017)Dementia prevention, intervention, and care Lancet 390 2673-1259

[6] Winblad B(2018)A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease Expert Opin Pharmacother 19 1245-289

[7] Pink J(2008)Systematic review of economic evaluations of Alzheimer’s disease medications Expert Rev Pharmacoecon Outcomes Res 8 273-S25

[8] O’Brien J(2014)Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia J Alzheimers Dis 42 S19-1236

[9] Robinson L(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 e1000097-245

[10] Longson D(2010)Systematic reviews: CRD's guidance for undertaking reviews in health care Lancet Infect Dis 10 226-1862

[1] Wimo A(2017)The worldwide costs of dementia 2015 and comparisons with 2010 Alzheimers Dement 13 1-7

[2] Guerchet M(2018)Dementia: assessment, management and support: summary of updated NICE guidance BMJ 361 k2438-90

[3] Ali G-C(2007)Cost–effectiveness of treatments for Alzheimer’s dementia Expert Rev Pharmacoecon Outcomes Res 7 83-612

[4] Wu Y-T(2013)Screening for cognitive impairment in older adults: a systematic review for the US Preventive Services Task Force Ann Intern Med 159 601-2734

[5] Prina AM(2017)Dementia prevention, intervention, and care Lancet 390 2673-1259

[6] Winblad B(2018)A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease Expert Opin Pharmacother 19 1245-289

[7] Pink J(2008)Systematic review of economic evaluations of Alzheimer’s disease medications Expert Rev Pharmacoecon Outcomes Res 8 273-S25

[8] O’Brien J(2014)Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia J Alzheimers Dis 42 S19-1236

[9] Robinson L(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 e1000097-245

[10] Longson D(2010)Systematic reviews: CRD's guidance for undertaking reviews in health care Lancet Infect Dis 10 226-1862